Safety, tolerability, and ocular hypotensive efficacy of QLS-111, a novel ATP-sensitive potassium channel opener added to latanoprost monotherapy – QC-111-203 “Apteryx” Clinical StudySafety, tolerability, and ocular hypotensive efficacy of QLS-111, a novel ATP-sensitive potassium channel opener added to latanoprost monotherapy – QC-111-203 “Apteryx” Clinical Study